383930.Kq
383930.KQ operates in the healthcare sector, specifically in the pharmaceuticals industry, and generates revenue primarily through the development, production, and sale of pharmaceutical products.
Business. 383930.KQ operates in the healthcare sector, specifically in the pharmaceuticals industry, and generates revenue primarily through the development, production, and sale of pharmaceutical products.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
383930.KQ operates in the healthcare sector, specifically in the pharmaceuticals industry, and generates revenue primarily through the development, production, and sale of pharmaceutical products.
The company's capital structure is characterized by a debt-to-equity ratio of 1.44, indicating a relatively high level of leverage. Its liquidity position is assessed as medium, with a current ratio of 0.52, suggesting that the company may face challenges in meeting its short-term obligations. The price-to-book ratio of 1.53 indicates that the market value of the company is 53% higher than its book value, which may reflect investor expectations of future growth or intangible assets.
Profitability metrics show that the company is currently unprofitable, with a return on equity of -11.07% and a return on assets of -3.07%. These figures are below the industry median for profitability, indicating that the company is underperforming relative to its peers in terms of generating returns for shareholders and utilizing its assets efficiently.
The company's revenue is concentrated in a single segment, as disclosed in its financial statements, with no significant geographic diversification reported. This lack of diversification may expose the company to higher risks associated with market-specific downturns or regulatory changes.
The company's growth trajectory is negative, with a decline in operating income and net income. The outlook for the current fiscal year indicates a continuation of this trend, with no significant improvement expected in the near term. The company's capital expenditure of -11.92 billion KRW suggests a reduction in investment in long-term assets, which may impact its ability to sustain growth in the future.
The company's risk assessment highlights a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt indicates that the company may need to secure additional financing to meet its obligations. However, the low dilution risk suggests that the company is not expected to issue a significant number of new shares in the near term, which could help maintain shareholder value.
Recent events, as disclosed in the company's financial filings, include a significant decline in operating and net income, which may be attributed to increased costs or reduced sales. The company has not disclosed any major strategic initiatives or new product launches that could drive future growth.
- The company is currently unprofitable, with a negative return on equity and return on assets.
- The company's liquidity position is medium, with a current ratio of 0.52, indicating potential challenges in meeting short-term obligations.
- The company's debt-to-equity ratio of 1.44 suggests a high level of leverage, which increases financial risk.
- The company's growth trajectory is negative, with a decline in operating and net income, and no significant improvement expected in the near term.
- The company's risk assessment indicates a medium liquidity risk and a low dilution risk.
- **margin_outlook_rationale**: The company's margin outlook is negative due to declining profitability and increased costs.
- **rd_outlook_rationale**: The company's R&D outlook is uncertain, as there is no significant investment in new product development disclosed.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- 383930.KQ Market data — financials · 2026-05-26